Biohaven Price to Free Cash Flow Ratio 2016-2022 | BHVN

Historical price to free cash flow ratio values for Biohaven (BHVN) since 2016. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Biohaven Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2023-01-31 19.09 0.00
2022-09-30 151.17 $-15.79 0.00
2022-06-30 145.71 $-8.46 0.00
2022-03-31 118.57 $-9.89 0.00
2021-12-31 137.81 $-12.88 0.00
2021-09-30 138.91 $-6.65 0.00
2021-06-30 97.08 $-13.10 0.00
2021-03-31 68.35 $-12.65 0.00
2020-12-31 85.71 $-12.04 0.00
2020-09-30 65.01 $-10.78 0.00
2020-06-30 73.11 $-8.87 0.00
2020-03-31 34.03 $-9.50 0.00
2019-12-31 54.44 $-7.86 0.00
2019-09-30 41.72 $-6.34 0.00
2019-06-30 43.79 $-6.75 0.00
2019-03-31 51.47 $-4.96 0.00
2018-12-31 36.98 $-1.71 0.00
2018-09-30 37.55 $-2.63 0.00
2018-06-30 39.52 $-0.77 0.00
2017-06-30 25.00 $-1.26 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.266B $0.463B
Biohaven Ltd. is a clinical-stage biopharmaceutical company. It focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases principally in the United States. Biohaven Ltd., formerly known as BIOHAVEN PHARM, is based in New Haven, Connecticut.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $153.147B 9.34
GSK (GSK) United Kingdom $71.894B 8.95
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.086B 18.92
Ginkgo Bioworks Holdings (DNA) United States $3.531B 0.00
Myovant Sciences (MYOV) United Kingdom $2.613B 0.00
Arcus Biosciences (RCUS) United States $1.618B 24.29
Emergent Biosolutions (EBS) United States $0.645B 5.07
ADC Therapeutics SA (ADCT) Switzerland $0.378B 0.00
Ambrx Biopharma (AMAM) United States $0.078B 0.00
Enzo Biochem (ENZ) United States $0.067B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.022B 0.00